NASDAQ:ATNX - Athenex Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$11.34 +0.40 (+3.66 %)
(As of 04/24/2019 04:48 AM ET)
Previous Close$10.94
Today's Range$10.79 - $11.49
52-Week Range$9.83 - $20.90
Volume251,800 shs
Average Volume260,908 shs
Market Capitalization$760.04 million
P/E RatioN/A
Dividend YieldN/A
Beta0.21
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and oral eribulin, an intravenous anticancer drug to treat certain patients with breast cancer and advanced liposarcoma. In addition, the company offers Src Kinase product candidates comprising KX2-391 ointments for actinic keratosis, skin cancers, and psoriasis; KX-01 oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and Pegtomarginase, an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is headquartered in Buffalo, New York.

Receive ATNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ATNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATNX
CUSIPN/A
Phone716-427-2950

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$89.10 million
Book Value$1.92 per share

Profitability

Net Income$-117,440,000.00
Net Margins-131.81%

Miscellaneous

Employees575
Market Cap$760.04 million
Next Earnings Date5/13/2019 (Estimated)
OptionableOptionable

Athenex (NASDAQ:ATNX) Frequently Asked Questions

What is Athenex's stock symbol?

Athenex trades on the NASDAQ under the ticker symbol "ATNX."

How were Athenex's earnings last quarter?

Athenex Inc (NASDAQ:ATNX) posted its quarterly earnings data on Monday, March, 11th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.21. The firm earned $21.27 million during the quarter. Athenex had a negative return on equity of 66.23% and a negative net margin of 131.81%. View Athenex's Earnings History.

When is Athenex's next earnings date?

Athenex is scheduled to release their next quarterly earnings announcement on Monday, May 13th 2019. View Earnings Estimates for Athenex.

What price target have analysts set for ATNX?

4 Wall Street analysts have issued 12-month price objectives for Athenex's shares. Their forecasts range from $15.00 to $27.00. On average, they expect Athenex's stock price to reach $20.6667 in the next year. This suggests a possible upside of 82.2% from the stock's current price. View Analyst Price Targets for Athenex.

What is the consensus analysts' recommendation for Athenex?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athenex in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Athenex.

Has Athenex been receiving favorable news coverage?

News articles about ATNX stock have trended somewhat positive on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Athenex earned a news sentiment score of 1.6 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days.

Who are some of Athenex's key competitors?

What other stocks do shareholders of Athenex own?

Who are Athenex's key executives?

Athenex's management team includes the folowing people:
  • Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D., Chairman & CEO (Age 59)
  • Mr. Jeffrey M. Yordon, COO & Pres of Athenex Pharmaceutical Division (Age 70)
  • Dr. Rudolf Kwan M.D., M.B., B.S., Exec. VP & Chief Medical Officer (Age 66)
  • Mr. Kam-Chung Leung GBS, LLD, OBE, JP, Strategic & Bus. Advisor (Age 67)
  • Dr. Allen Barnett, Co-Founder & Pres Emeritus

When did Athenex IPO?

(ATNX) raised $72 million in an IPO on Wednesday, June 14th 2017. The company issued 6,000,000 shares at $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan served as the underwriters for the IPO and ICBC International was co-manager.

Who are Athenex's major shareholders?

Athenex's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Strs Ohio (0.05%). Company insiders that own Athenex stock include Jeffrey Yordon, Jinn Wu, Johnson Yiu Nam Lau, Manson Fok, Randoll Sze, Rudolf Kwan, Sheldon Trainor-Degirolamo, Song-Yi Zhang and William Wei Zuo. View Institutional Ownership Trends for Athenex.

Which major investors are selling Athenex stock?

ATNX stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have sold Athenex company stock in the last year include Sheldon Trainor-Degirolamo and Song-Yi Zhang. View Insider Buying and Selling for Athenex.

How do I buy shares of Athenex?

Shares of ATNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Athenex's stock price today?

One share of ATNX stock can currently be purchased for approximately $11.34.

How big of a company is Athenex?

Athenex has a market capitalization of $760.04 million and generates $89.10 million in revenue each year. The company earns $-117,440,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Athenex employs 575 workers across the globe.

What is Athenex's official website?

The official website for Athenex is http://www.athenex.com.

How can I contact Athenex?

Athenex's mailing address is 1001 Main Street Suite 600, Buffalo NY, 14203. The company can be reached via phone at 716-427-2950.


MarketBeat Community Rating for Athenex (NASDAQ ATNX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  193 (Vote Outperform)
Underperform Votes:  189 (Vote Underperform)
Total Votes:  382
MarketBeat's community ratings are surveys of what our community members think about Athenex and other stocks. Vote "Outperform" if you believe ATNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel